Lung Cancer | Specialty

Small-Cell Lung Cancer: Future Directions in Care

February 28th 2020

Emerging Treatment Options for SCLC

February 28th 2020

Lurbinectedins Role in Managing SCLC

February 28th 2020

Treatment of Relapsed/Refractory SCLC

February 28th 2020

Chemoimmunotherapy for ES SCLC: CASPIAN Trial

February 28th 2020

Chemoimmunotherapy for ES SCLC: IMpower133 Trial

February 28th 2020

Addressing the Aggressive Nature of SCLC

February 28th 2020

Optimal Management of Limited-Stage SCLC

February 28th 2020

SCLC Overview: Presentation, Staging, and Complications

February 28th 2020

Dr. Chae on Using Crizotinib to Treat MET+ NSCLC

February 28th 2020

Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.

Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLC

February 28th 2020

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Immunotherapy Makes Waves in Small Cell Lung Cancer

February 28th 2020

Alain C. Mita, MD, discusses the impact of immunotherapy in the frontline and recurrent settings for patients with small cell lung cancer.

FDA Panel Narrowly Supports Ramucirumab/Erlotinib Combo in Frontline EGFR+ NSCLC

February 27th 2020

The FDA's Oncologic Drugs Advisory Committee voted 6 to 5 in favor of intravenous ramucirumab injection for use in combination with erlotinib as a frontline treatment for patients with metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.

Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer

February 27th 2020

Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.

FDA Grants Brigatinib Priority Review for Frontline ALK+ NSCLC

February 24th 2020

The FDA has granted a priority review designation to a supplemental New Drug Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Osimertinib Shows Efficacy in CNS and Leptomeningeal Mets in EGFR+ NSCLC

February 21st 2020

Osimertinib, at 160 mg daily, demonstrated efficacy in the central nervous system and a manageable safety profile in patients with EGFR-mutant advanced non–small cell lung cancer who have leptomeningeal metastases.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Immunotherapy Advances to Frontline in NSCLC, But More Work Remains

February 20th 2020

Ronald Natale, MD, expands on the recent developments with immunotherapy in advanced non–small cell lung cancer.

Dr. Mirhadi on Novel Radiation Technologies in NSCLC

February 20th 2020

Amin J. Mirhadi, MD, discusses novel radiation approaches that are being used in non–small cell lung cancer.

Dr. Mita on Emergence of Checkpoint Inhibitors SCLC

February 20th 2020

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.